cryptococcosis

Diagnosis of pulmonary cryptococcosis without dissemination is unusual among children.

Clinical experience with new antifungal agents in managing cryptococcosis is limited.

It is capable of causing disease (cryptococcosis) in non-immunocompromised people.

A similar appearance can be associated with histoplasmosis, cryptococcosis, and coccidioidomycosis.

They have also been found to carry Cryptococcus neoformans which can cause cryptococcosis in humans.

Overall in vitro resistance to antifungal agents used to treat cryptococcosis remains uncommon (347).

Both yeasts are human pathogens, responsible for cryptococcosis, and are now cosmopolitan in distribution.

Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome.

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

When cryptococcosis occurs in the HIV-infected patient, disseminated disease is common.

Infection with C. neoformans is termed cryptococcosis.

This is true, but not necessarily panic-inducing, given the exceedingly rare incidences of respiratory infections like cryptococcosis.

Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Consider evaluation for TB and cryptococcosis.

In a European study, none of 39 subjects whose antifungal therapy was discontinued had a recurrence of cryptococcosis.

Cryptococcus neoformans is a significant pathogen of immunocompromised people causing the disease termed cryptococcosis.

Extrapulmonary cryptococcosis.

In both HIV-infected adults and children, meningoencephalitis is the most common initial manifestation of cryptococcosis.

Because of rapidly developing resistance, flucytosine alone should never be used to treat cryptococcosis (EII).

Studies in adults clearly show the role of increased intracranial pressure in death associated with CNS cryptococcosis (355,366).

Symptoms of meningitis are similar to those described for meningitis presenting as the initial manifestation of cryptococcosis.

These include aspergilloses, candidoses, coccidioidomycosis, cryptococcosis, histoplasmosis, mycetomas, and paracoccidioidomycosis.

Monitoring for and managing raised intracranial pressure is crucial to the optimal management of CNS cryptococcosis (see below).

Limited data are available for the newer triazoles, voriconazole and posaconazole, as either primary or follow-up therapy for patients with cryptococcosis.